FDA Peptide Reclassification 2026: BPC-157 & the 503A List

PCAC July 2026 Review — Seven Peptides at a Glance

Uses listed are the indications considered in the FDA/PCAC compounding docket — they are not therapeutic claims. Vote tallies are as reported in regulatory-law and news coverage of the meeting; all recommendations are advisory pending FDA rulemaking. Remy Peptides is an informational publisher.

Is BPC-157 FDA Approved?

No. BPC-157 is not an FDA-approved drug. It holds no approved indication in the United States. The FDA had listed BPC-157 among bulk drug substances that “may present significant safety risks” — the interim Category 2 designation the agency applied to more than a dozen peptides in 2023 — but the nomination was withdrawn in April 2026, moving BPC-157 to the FDA’s separate “nominated but withdrawn” list. PCAC considered it with six other peptides for the 503A Bulks List on July 23–24, 2026, and voted 8–6 (one abstention) to recommend inclusion for the evaluated use of ulcerative colitis.

Is BPC-157 “banned”? That label is too broad. It is not FDA approved and is not yet on the 503A Bulks List. PCAC's July 2026 recommendation was advisory and non-binding — notably, FDA's own scientific review staff opposed inclusion — and any binding list change requires notice-and-comment rulemaking, which commonly takes a year or more.

TB-500, MOTS-c, and KPV are in the same regulatory position: none is FDA-approved, all three had their Category 2 nominations withdrawn in April 2026 (the FDA now lists them among substances nominated but withdrawn, safety-risk record intact), and all three were likewise recommended by PCAC on July 23 — TB-500 and KPV at 8–6 (one abstention each), MOTS-c at 7–5 (two abstentions).

Category 2 was the FDA designation for bulk substances with identified significant safety risks for compounding use — not on the compounding-eligible list, and not an approval decision. The four peptides here were placed in Category 2 in 2023 and then removed in April 2026 when the nominations were withdrawn; none is an approved drug in any jurisdiction. This is separate from the research-use lane: the 503A framework governs pharmacy compounding for human prescriptions, while research-grade peptides are supplied for in-vitro laboratory research use only.

What Is the PCAC and Why Does This Meeting Matter?

The Pharmacy Compounding Advisory Committee is a standing FDA advisory body that evaluates active pharmaceutical ingredients (APIs) for inclusion on the 503A Bulks List — the list of bulk drug substances that licensed compounding pharmacies may legally use to prepare medications for individual patients with valid prescriptions. The committee reviews each candidate against four criteria laid out in Section 503A(b)(1)(A)(i) of the Federal Food, Drug, and Cosmetic Act: physical and chemical characterization, safety, evidence of effectiveness, and historical use in compounding.

PCAC outcomes are advisory recommendations to the FDA, not final rulings. A positive vote does not automatically place a peptide on the list. A negative vote does not by itself ban it. The agency typically converts PCAC recommendations into Federal Register rulemaking over the following 12 to 24 months — first a proposed rule, then a public comment window, then a final rule. By that path a July 2026 vote points to a likely formal outcome in late 2026 or 2027. Meeting materials and the official agenda are posted on the FDA advisory committee calendar at fda.gov.

The July 2026 meeting matters because PCAC considered this slate of peptides in a single docket and diverged from FDA's scientific reviewers on six of seven candidates. The meeting itself did not approve a drug or create a final rule. Any binding 503A list change must come through later FDA action or Federal Register rulemaking; some regulatory commentators expect the agency to exercise informal enforcement discretion for the six recommended peptides in the interim, but the FDA has not announced any such policy.

Day 1 — July 23, 2026: BPC-157, TB-500, MOTS-c, KPV

Day 1 covers four peptides framed around tissue repair, regeneration, and metabolic indications. The FDA docket evaluates each compound as the free base and the acetate salt where applicable, because compounders sometimes source one form and substitute the other based on stability or supplier availability.

Ahead of the meeting, the FDA posted substance-specific briefing documents for each Day 1 peptide — BPC-157, TB-500, MOTS-c, and KPV — alongside an introduction and Day 2 packages for Semax, Epitalon, and Emideltide (DSIP). These background packages set out the evidence the committee weighs against the four 503A criteria.

BPC-157 — Use Under Review: Ulcerative Colitis

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a 15-amino-acid fragment of a protein found in human gastric juice. Preclinical literature, primarily from a small group of laboratories in Croatia, reports effects on angiogenesis, tendon and ligament healing, and gastrointestinal tissue repair. The PCAC docket evaluates the indication of ulcerative colitis, the use with the deepest historical compounding signal.

The evidence picture is contested. A February 3, 2026 STAT News investigation argued the published BPC-157 literature is concentrated in a narrow author network with limited independent replication and minimal controlled human data. The NCBI PMC review at PMC12446177 catalogues mechanisms across rodent injury models. BPC-157 has no FDA-approved indication. The 503A discussion concerns compounding policy, not approved therapeutic status.

TB-500 — Use Under Review: Wound Healing

TB-500 is a synthetic 17-amino-acid fragment derived from Thymosin Beta-4 (Tβ4), a naturally occurring regulatory peptide implicated in actin sequestration, cell migration, and angiogenesis. The PCAC reviews TB-500 for wound healing. Orthopaedic and dermatologic compounding has been the primary historical use; the PMC12753158 orthopaedic review surveys preclinical and pilot human data.

Like BPC-157, TB-500 lacks any FDA-approved indication. The Day 1 materials focused on identity and characterization issues involving TB-500 (the fragment) and full Thymosin Beta-4. Those questions sit at the centre of the 503A bulks analysis.

MOTS-c — Uses Under Review: Obesity and Osteoporosis

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome. The PCAC docket evaluates two indications: obesity and osteoporosis. Preclinical work, including the mechanism paper indexed as PMID 41520850, links MOTS-c to AMPK activation, insulin sensitivity, and bone-cell signaling.

MOTS-c sits in a different regulatory category than BPC-157 or TB-500. The compounding history is shorter and the published human data thinner, which historically weighs against 503A inclusion. The committee will likely focus on whether a stable manufacturing and identity standard exists for the peptide, since synthesis and storage parameters for mitochondrial-derived peptides remain less standardized than for traditional therapeutic peptides.

KPV (Lys-Pro-Val) — Uses Under Review: Wound Healing and Inflammatory Conditions

KPV is a tripeptide (Lys-Pro-Val) corresponding to the C-terminal tripeptide of α-MSH (alpha-melanocyte-stimulating hormone). Preclinical models describe anti-inflammatory effects in colitis and skin inflammation, and KPV has appeared in topical compounding for dermatologic and gastrointestinal applications. The PCAC reviews the indications of wound healing and inflammatory conditions.

As a short peptide, KPV is easier to characterize chemically than BPC-157 or TB-500, which works in its favour on the identity criterion. Whether the published efficacy and safety record is sufficient to support 503A inclusion remains the contested question.

Day 2 — July 24, 2026: Semax, Epitalon, DSIP

Day 2 covers three peptides oriented around neurological and sleep-related indications. The compounding history concentrated in nootropic clinics and longevity-focused practices is the policy backdrop.

Semax — Uses Under Review: Cerebral Ischemia, Migraine, Trigeminal Neuralgia

Semax is a heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-7) with an extended C-terminal proline-glycine-proline sequence. Originally developed in Russia, Semax has appeared in regional therapeutic use for cerebrovascular and neurological indications. The PCAC reviews cerebral ischemia, migraine, and trigeminal neuralgia — each evaluated for the free base and acetate forms.

The published clinical literature on Semax is predominantly Russian-language and dates from regional clinical practice rather than FDA-aligned trials. For a 503A bulks decision, the committee weighs whether that body of evidence meets the “recognized historical use in compounding” criterion under US conditions. Full mechanism, trial, and evidence-limit detail: Semax research profile.

Epitalon / Epithalon — Use Under Review: Insomnia

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in Russia and studied for its proposed effects on melatonin synthesis, telomerase activity, and pineal-gland signaling. The PCAC reviews the indication of insomnia, with the free base and acetate forms evaluated separately.

Epitalon’s research literature shares the Semax profile: a regional clinical and gerontology record concentrated in a small number of institutions, with limited replication in independent Western trials. The 503A decision is therefore about the strength of US compounding use plus identity and assay standards, not about pivotal trial efficacy. Full mechanism, telomerase, and evidence-limit detail: Epitalon research profile.

DSIP / Emideltide — Uses Under Review: Opioid Withdrawal, Chronic Insomnia, Narcolepsy

DSIP (Delta Sleep-Inducing Peptide), referred to in the PCAC docket under the name Emideltide for the proposed compounded form, is a nonapeptide originally isolated from rabbit cerebral venous blood and named for its effect on EEG delta-wave activity. The PCAC reviews three indications: opioid withdrawal, chronic insomnia, and narcolepsy.

DSIP/Emideltide has the broadest indication slate of the seven peptides on the docket, and also one of the longest historical compounding records in the sleep and addiction-medicine niches. The breadth of indications cuts both ways: it gives the compounding side multiple use-history threads to point to, but it also gives the committee multiple efficacy questions to evaluate before voting on inclusion.

What “PCAC Review” Means in Practice

The PCAC advisory meeting is one step in a multi-stage regulatory cycle. The mechanical sequence is consistent across compounded peptide reviews:

1. FDA docket and meeting materials published in advance on the advisory committee calendar.
2. Public meeting — presentations by FDA staff, industry stakeholders, and clinicians; open comment period; committee deliberation; advisory vote on each candidate.
3. FDA review of PCAC recommendation — weeks to months, during which the agency drafts proposed rulemaking aligned with or departing from the committee’s advisory vote.
4. Federal Register proposed rule — the FDA’s formal position on inclusion or exclusion is published, opening a public comment window (typically 60 to 90 days).
5. Final rule — after comment review, the FDA publishes the binding determination. Inclusion or exclusion takes legal effect on the date the final rule is enforceable.

Inclusion on the 503A Bulks List allows licensed compounding pharmacies in the United States to use the peptide as an active pharmaceutical ingredient when preparing patient-specific prescriptions. The peptide remains unapproved as a finished drug — there is still no brand-name product on the US market — but the compounding pathway becomes available with documented sourcing and prescriber oversight. Exclusion blocks that pathway. The FDA Law Blog provides a useful primer on the broader 503A/503B compounding landscape at thefdalawblog.com, and OptiMantra covers the Category 2 shift context.

What Triggered This — The April 2026 Category 2 Removal

The July PCAC docket followed a concrete event. On April 15–16, 2026, the FDA removed 12 peptides from Category 2 of the 503A Do-Not-Compound list because the underlying nominations had been withdrawn: BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500. Reuters reported the removal at reuters.com. Coming off the list does not approve any of these compounds as finished drugs.

A Federal Register notice on April 16, 2026 scheduled the July 23–24 PCAC meeting to consider seven of the removed peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon. The notice is filed under 2026-07361. The April action and the later advisory meeting were separate steps; any binding list determination still requires FDA action.

Separately, on April 1, 2026, the FDA reissued guidance reminding 503A and 503B compounders that the GLP-1 compounding-exemption conditions must now be met in full, given that semaglutide and tirzepatide have come off the shortage list and supply has stabilized. That reminder set the tone for the enforcement posture that followed through April and May.

The 503B Bulks Exclusion Proposal in Context

The PCAC peptide review does not happen in isolation. On April 30, 2026, the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the parallel list governing outsourcing facilities that compound at scale — citing “no clinical need” now that the approved products are available and shortages have resolved. The proposal was published in the Federal Register on May 1, 2026 (notice 2026-08552); Reuters reported it at reuters.com. The proposed exclusion closes the compounded GLP-1 lane that expanded during the 2022 to 2024 shortage period.

Three weeks later, on May 18, 2026, SafeMedicines published a warning about illicit distribution tied to ProRx, naming companies operating outside the regulatory framework for compounded GLP-1 and peptide product. The full warning is at safemedicines.org.

Read together, the April 30 proposed rule and the May 18 enforcement notice show an enforcement trend rather than isolated incidents. The July 23-24 PCAC review belongs to that broader compounding-policy context, but the committee's recommendations remain advisory. Binding inclusion or exclusion requires subsequent FDA rulemaking.

What This Means for Researchers and Clinics

The practical regulatory takeaway is that the meeting did not itself change legal status. Any binding inclusion or exclusion must come through FDA action or Federal Register rulemaking. This article will track those primary-source changes without treating advisory discussion as a final rule.

For US researchers studying these compounds in academic or industry-sponsored settings, the PCAC process does not directly govern preclinical or clinical research. Investigator-initiated trials and IND-enabled studies continue under their own framework. The bulks list is a compounding-supply question; the research lane is a separate regulatory track.

Research vs compounding context. The 503A and 503B pathways concern compounding. Laboratory and clinical research operate under separate institutional and regulatory requirements. The PCAC meeting did not create a general research-use exemption, and an RUO label alone is not authorization.

For the broader UAE peptide landscape and how research-use compliance interacts with current GLP-1 and metabolic peptide research, see our peptide trends in the UAE 2026 analysis and the peptide legality guide for Dubai.

PCAC vote outcomes — six of seven peptides recommended

The July 23–24, 2026 PCAC meeting concluded with the committee recommending six of the seven peptides for inclusion on the 503A Bulks List, in both free base and acetate forms where applicable: BPC-157 (8–6, one abstention; evaluated use: ulcerative colitis), KPV (8–6, one abstention; wound healing and inflammatory conditions), TB-500 (8–6, one abstention; wound healing), MOTS-c (7–5, two abstentions; obesity and osteoporosis), Epitalon (insomnia), and Semax (8–5, one abstention; cerebral ischemia, migraine, trigeminal neuralgia). Emideltide (DSIP) was the only candidate voted down, 6–7 with one abstention.

Two structural facts frame these outcomes. First, FDA's own scientific review staff recommended against inclusion of all seven peptides in the briefing documents, so the committee's votes diverged from the agency reviewers on six compounds — a split the FDA is not obliged to resolve in the committee's favor. Second, the votes are non-binding: inclusion requires notice-and-comment rulemaking in the Federal Register, a cycle that commonly takes a year or more. Some regulatory commentators anticipate informal enforcement discretion for the six recommended peptides while rulemaking is pending, but the FDA has announced no such policy. None of these compounds gained an approved indication, and the votes do not change the research-only status of any research-grade peptide.

Sources: FDA meeting page and materials; McDermott Will & Schulte meeting analysis; Buchanan Ingersoll & Rooney client alert.